1. 3.7GBq 1.3mSv 1/10 d 1 5
11.b a. b. 100% d. e. 12. b, e a. b. LET LET 30cGy/h(0.5cGy/min) G2 G2 () d. 1cGy/ 100cGy/ e.
13. a, c a. b. LET / d. LQ e. LQ 14. d, e a. b. d. e. 15. a NIPPON ACTA RADIOLOGICA 2002 ; 62 : 188-193 Table 2 Fig 11 15 16e 2mm 1mm 4
1 (stereotactic radiosurgery:srs) (stereotactic tadiotherapy:srt) a. b. d. e. 17. b,c a. eloquent area 1 1 18~25Gy 5cm AVM 25Gy a. 20Gy 15Gy b. 3cm 3~4 d. 1 12-18Gy (12-14Gy) 18d,e germinoma a. b. d. 50-56Gy e. 50Gy 10~20Gy 19 a. 30~35Gy 20Gy (nitrosourea,vincristine,procarbazine,cisplatin) 25Gy b. c. d. e. 20c 1 1
a. b. 2 d. 16 20 21d a. 70 80 b. c.45gy d. e.40gy 22d a.2.2% b.8.0% c.15.8% d.22.5% e.10.8% 23b a. b. c. d. e.cr PCI 30 25Gy/10fr 2.5Gy 24 a c a. b. c. GEM d. e. (19 36%) 25 T2 T4 N1 M0 TNM 21 25 26. c, d. SVC PS( e ) JASTRO2003 stage (NSCLC)
Pritchard(Ann Inter Med 125:723-729;1996) Furuse(J Clin Oncol 17:2692-2699;1999) CT RT vs RT alone meta-analysis CT RT RT alone MST ( 1.7 ) concurrent vs sequential RCT concurrent MST ( 3.2 ) c b b a d ( ) ( ) (pp. 268f.) 2002 () (p. 621) (Sause Chest 117:358-364;2000) d a c 27. c. 2002 19 b. 2. (pp. 691f.) c. 28. a, c. a. 2002 (p. 695) 1 (pp. 700) 29. c. 2002 (pp. 694f.) 4 6 Gy mm 10 mm mm 3 5 Gy Gy ( ) 2 2.5 Gy 30. d. ( 2002 (pp. 774f.)) 2 (pp. 366f.) T2 4 T2 4 primary target volume cm target volume
26-30 d
36 c. X (Papillon ) T3 T2N0M0(Dukes A) neoadjuvant 37 e. (Heyman Packing ) 38 e FIGO Host Hb 39 e 40 a 40 lymphcyte predominant nodular sclerosis B 3
50mm/